Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Tuberculosis, drug resistance, and the history of modern medicine.N Engl J Med. 2012; 367: 931-936
- Treatment of tuberculosis with streptomycin; a summary of observations on one hundred cases.J Am Med Assoc. 1946; 132: 778-782
- The history of tuberculosis.Respir Med. 2006; 100: 1862-1870
- Streptomycin resistance in pulmonary tuberculosis.Br Med J. 1948; 11: 1009-1015
- Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update.World Health Organization, Geneva2017 (Available at:)
- Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis.J Antimicrob Chemother. 2014; 69: 292-302
- Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.Antimicrob Agents Chemother. 2002; 46: 267-274
- The Maxwell Finland lecture: for the duration-- rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile.Clin Infect Dis. 2008; 46: 491-496
- Combination therapy for treatment of infections with gram-negative bacteria.Clin Microbiol Rev. 2012; 25: 450-470
- Antibiotic combinations: should they be tested?.Clin Microbiol Rev. 1988; 1: 139-156
- Trimethoprim-sulfamethoxazole: in vitro microbiological aspects.J Infect Dis. 1973; 128: S442-S462
- Mechanism of action of trimethoprim-sulfamethoxazole—I.J Infect Dis. 1973; 128: S433-S436
- Three decades of β-lactamase inhibitors.Clin Microbiol Rev. 2010; 23: 160-201
- Synergistic activity of colistin-containing combinations against colistin-resistant Enterobacteriaceae.Antimicrob Agents Chemother. 2018; https://doi.org/10.1128/AAC.00873-18
- Studies on antibiotic synergism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci.J Clin Invest. 1971; 50: 2580-2584
- Agents that increase the permeability of the outer membrane.Microbiol Rev. 1992; 56: 395-411
- Colistin and fusidic acid, a novel potent synergistic combination for treatment of multidrug-resistant Acinetobacter baumannii infections.Antimicrob Agents Chemother. 2015; 59: 4544-4550
- Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides.Antimicrob Agents Chemother. 1999; 43: 639-646
- Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis.Antimicrob Agents Chemother. 1995; 39: 1984-1987https://doi.org/10.1128/AAC.39.9.1984
- Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications.Circulation. 2015; 132: 1435-1486
- The role of rifampin against staphylococcal biofilm infections in vitro, in animal models, and in orthopedic device-related infections.Antimicrob Agents Chemother. 2018; 63https://doi.org/10.1128/AAC.01746-18
- Resistance to rifampicin: a review.J Antibiot (Tokyo). 2014; 67: 625-630
- Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.J Infect Dis. 2013; 207: 786-793
- Combination treatment with meropenem plus levofloxacin is synergistic against pseudomonas aeruginosa infection in a murine model of Pneumonia.J Infect Dis. 2015; 211: 1326-1333
- Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant enterococcus faecium from renal transplant patients with infected urinary stents.Antimicrob Agents Chemother. 2013; 57: 1518-1520
- Activity of antimicrobial combinations against KPC-2-Producing Klebsiella pneumoniae in a rat model and time-kill assay.Antimicrob Agents Chemother. 2015; 59: 4301-4304
- Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology.J Antimicrob Chemother. 2017; 72: 2775-2781
- Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.Antimicrob Agents Chemother. 2011; 55: 5134-5142
- Synergy testing by etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii.Antimicrob Agents Chemother. 2010; 54: 4678-4683
- β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.J Antimicrob Chemother. 2014; 70: 1738-1743
- Comparison of techniques for measurement of in vitro antibiotic synergism.J Infect Dis. 1979; 140: 629-633
- Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus.Antimicrob Agents Chemother. 1984; 26: 220-223
- Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.Antimicrob Agents Chemother. 1996; 40: 1914-1918
- Methodological variation in antibiotic synergy tests against enterococci.J Clin Microbiol. 1981; 13: 73-75
- Synergism testing: broth microdilution checkerboard and broth macrodilution methods.in: Leber A.L. Clinical microbiology procedures handbook. 4th edition. ASM Press, Washington, DC2016: 5.16.1-5.16.23
- Performance standards for antimicrobial susceptibility testing.29th edition. Clinical and Laboratory Standards Institute, Wayne (PA)2019 (CLSI Supplement M100)
- Synergy, antagonism, and what the chequerboard puts between them.J Antimicrob Chemother. 2003; 52: 1
- M07: methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically.11th edition. Clinical and Laboratory Standards Institute, Wayne (PA)2018
- The search for synergy: a critical review from a response surface perspective.Pharmacol Rev. 1995; 47: 331-385
- A method for testing for synergy with any number of agents.J Infect Dis. 1978; 137: 122-130
- Synergy with double and triple antibiotic combinations compared.J Antimicrob Chemother. 1983; 12: 555-563
- Performance standards for antimicrobial disk susceptibility tests.13th edition. Clinical and Laboratory Standards Institute, Wayne (PA)2018 (CLSI Standard M02)
- Antimicrobial combinations.in: Lorian V. Antibiotics in laboratory medicine. Lippincott Williams & Wilkins, 2005: 365-440
- Three dimensional checkerboard synergy analysis of colistin, meropenem, tigecycline against multidrug-resistant clinical Klebsiella pneumonia isolates.PLoS One. 2015; 10https://doi.org/10.1371/journal.pone.0126479
- When does 2 plus 2 equal 5? A review of antimicrobial synergy testing.J Clin Microbiol. 2014; 52: 4124-4128
- Etest.in: Leber A. Clinical microbiology procedures handbook. 4th edition. ASM Press, Washington, DC2016: 5.3
- Comparison of 3 Etest® methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species.Diagn Microbiol Infect Dis. 2013; 77: 220-226
- Time-kill assay for determining synergy.in: Leber A.L. Clinical microbiology procedures handbook. 4th edition. ASM Press, Washington, DC2016: 5.14.3.1-5.14.3.6
- Methods for determining bactericidal activity of antimicrobial agents; approved guideline. CLSI document M26-A.Clinical and Laboratory Standards Institute, Wayne, PA1999
- Pre-clinical in vitro infection models.Curr Opin Pharmacol. 2017; 36: 100-106
- In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.J Antimicrob Chemother. 1985; 15: 125-130
- Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.J Antimicrob Chemother. 2017; 72: 1415-1420
- Combating carbapenem-resistant Acinetobacter baumannii by an optimized imipenem-plus-Tobramycin dosage regimen: prospective validation via hollow-fiber infection and mathematical modeling.Antimicrob Agents Chemother. 2018; 62https://doi.org/10.1128/AAC.02053-17
- Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.Antimicrob Agents Chemother. 2008; 52: 2486-2496
- Polymyxin combinations combat Escherichia coli harboring mcr-1 and blaNDM-5: preparation for a postantibiotic era.MBio. 2017; 8 ([pii:e00540-17])
- Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?.Antimicrob Agents Chemother. 2017; 61https://doi.org/10.1128/AAC.02243-16
- In vivo efficacy of plazomicin alone or in combination with meropenem or tigecycline against Enterobacteriaceae isolates exhibiting various resistance mechanisms in an immunocompetent murine septicemia model.Antimicrob Agents Chemother. 2018; 62https://doi.org/10.1128/AAC.01074-18
- Animal model pharmacokinetics and pharmacodynamics: a critical review.Int J Antimicrob Agents. 2002; 19: 261-268
- Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases.BMC Infect Dis. 2006; 6: 55
- Studies on antibiotic synergism against enterococci.J Clin Invest. 1971; https://doi.org/10.1172/JCI106758
- Aminoglycoside resistance in enterococci.Clin Infect Dis. 2000; 31: 586-589
- Penicillins and β-lactamase inhibitors.in: Bennett J.E. Dolin R. Blaser M.J. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, updated edition. 8th edition. Saunders, Philadelphia2015: 263-277
- Sulfonamides and trimethoprim.in: Bennett J.E. Dolin R. Blaser M.J. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, updated edition. 8th edition. Saunders, Philadelphia2015: 410-418
- Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing klebsiella pneumoniae by in vitro time-kill experiments.Antimicrob Agents Chemother. 2014; 58: 1757-1762
- In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.Antimicrob Agents Chemother. 2015; 59: 2515-2524
- Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-β-lactamase-producing Klebsiella pneumoniae isolates?.Antimicrob Agents Chemother. 2009; 53: 2133-2135
- Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.Pharmacotherapy. 2015; 35: 34-42
- Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp).J Infect. 2017; 74: 103-106
- Clinical significance of in vitro synergism between antibiotics in gram-negative infections.Antimicrob Agents Chemother. 1972; 2: 470-475
- Colistin-resistant Enterobacteriaceae infections: clinical and molecular characterization and analysis of in vitro synergy.Diagn Microbiol Infect Dis. 2017; 87: 253-257
- Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.Antimicrob Agents Chemother. 2014; 58: 2322-2328
- Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.Lancet Infect Dis. 2017; 17: 726-734
- Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.Lancet. 2005; 366: 463-471
- Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms.Paediatr Respir Rev. 2007; 8: 256-261
- Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: “the motion for.Paediatr Respir Rev. 2007; 8: 249-255
- Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: systematic review and meta-analysis: mortality due to KPC Klebsiella pneumoniae infections.J Infect. 2018; 76: 438-448
Article info
Publication history
Published online: June 12, 2019
Footnotes
Disclosure Statement: TECAN (Morrisville, NC) provided an HP D300 digital dispenser and associated consumables for use by JEK's research group. Tecan had no role in article preparation or decision to publish.
Funding: Dr. T. Brennan-Krohn's synergy research is supported by a National Institute of Allergy and Infectious Diseases career development award (1K08AI132716).
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
